Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc. (RARE) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · RARE · as of Sep 30, 2025
Ownership Breakdown
335
Institutional Holders
▼ 10 vs Q2
$2.87B
Total Inst. Value
▼ $551.26M vs Q2
98.49M
Shares Outstanding
freeFloat 95.95%
95.48M
13F Shares Held
▲ 1.34M vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
RARE largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
VANGUARD GROUP INC pharmaceutical preparations | 10.13M | 10.29% | 10.29% | $304.79B | Nov 7, 2025 | ▼ 80.7K |
FMR LLC pharmaceutical preparations | 7.28M | 7.40% | 7.40% | $219.08B | Nov 13, 2025 | ▲ 4.68M |
BLACKROCK, INC. pharmaceutical preparations | 6.43M | 6.53% | 6.53% | $193.27B | Nov 12, 2025 | ▲ 169.1K |
JPMORGAN CHASE & CO pharmaceutical preparations | 4.01M | 4.07% | 4.07% | $120.66B | Nov 26, 2025 | ▲ 750.6K |
SANDS CAPITAL MANAGEMENT, LLC pharmaceutical preparations | 3.77M | 3.83% | 3.83% | $113.40B | Nov 13, 2025 | ▼ 173.6K |
STATE STREET CORP pharmaceutical preparations | 3.69M | 3.75% | 3.75% | $111.07B | Nov 14, 2025 | ▲ 1.12M |
RTW INVESTMENTS, LP pharmaceutical preparations | 3.26M | 3.31% | 3.31% | $98.01B | Nov 14, 2025 | ▲ 1.55M |
BAKER BROS. ADVISORS LP pharmaceutical preparations | 2.77M | 2.82% | 2.82% | $83.40B | Nov 14, 2025 | — held |
PRICE T ROWE ASSOCIATES INC /MD/ pharmaceutical preparations | 2.31M | 2.35% | 2.35% | $69.49B | Nov 14, 2025 | ▼ 576.1K |
JACOBS LEVY EQUITY MANAGEMENT, INC pharmaceutical preparations | 2.17M | 2.20% | 2.20% | $65.21B | Nov 17, 2025 | ▲ 1.86M |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
31
Increased
+16.55M shares2
New Positions
first time holders15
Decreased
−6.08M shares0
Sold Out
fully exitedNet shares change (top 50)
+10.47M
+16.55M / −6.08M
Net new holders
+18
2 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
RARE insider trading · insider activity
Source: SEC Form 4
Insiders have been primarily selling shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
30
Buy transactions
5
Sell transactions
6.00
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Horn Howard Chief Financial Officer | Jun 1, 2026 | Sale | 4,653 | $23.77 | $110.6K | 105.7K | Form 4 ↗ |
Fust Matthew K director | May 14, 2026 | Award | 7,751 | — | — | 33.7K | Form 4 ↗ |
Fust Matthew K director | May 14, 2026 | Award | 14,058 | $25.80 | $362.7K | 14.1K | Form 4 ↗ |
SULIMAN SHEHNAAZ director | May 14, 2026 | Award | 7,751 | — | — | 33.7K | Form 4 ↗ |
SULIMAN SHEHNAAZ director | May 18, 2026 | Sale | 5,740 | $25.12 | $144.2K | 28.0K | Form 4 ↗ |
SULIMAN SHEHNAAZ director | May 14, 2026 | Award | 14,058 | $25.80 | $362.7K | 14.1K | Form 4 ↗ |
Ray Amrit director | May 14, 2026 | Award | 7,751 | — | — | 31.1K | Form 4 ↗ |
Ray Amrit director | May 14, 2026 | Award | 14,058 | $25.80 | $362.7K | 14.1K | Form 4 ↗ |
Sanders Corazon (Corsee) D. director | May 14, 2026 | Award | 7,751 | — | — | 23.1K | Form 4 ↗ |
Sanders Corazon (Corsee) D. director | May 14, 2026 | Award | 14,058 | $25.80 | $362.7K | 14.1K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Ultragenyx Pharmaceutical Inc. (RARE) is primarily owned by institutional investors, who hold approximately 97.0% of total shares outstanding. Company insiders own approximately 4.05%, while retail and public investors account for the remaining 0.00%.
The largest institutional shareholder of Ultragenyx Pharmaceutical Inc. is VANGUARD GROUP INC, holding approximately 10.13 million shares — equal to 10.29% of outstanding shares — as of September 30, 2025.
A total of 335 institutional investors currently hold RARE stock, with a combined institutional value of approximately $2.87 billion as of the most recent 13F filing period.
Frequently asked questions
RARE ownershipUltragenyx Pharmaceutical Inc. (RARE) is primarily owned by institutional investors, who hold approximately 97.0% of shares. The largest shareholder is VANGUARD GROUP INC with a 10.29% stake. Company insiders hold 4.05%. Data sourced from SEC Form 13F as of September 30, 2025.